International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease

Pablo A. Olivera, Stephane Zuily, Paulo G. Kotze, Veronique Regnault, Sameer Al Awadhi, Peter Bossuyt, Richard B. Gearry, Subrata Ghosh, Taku Kobayashi, Patrick Lacolley, Edouard Louis, Fernando Magro, Siew C. Ng, Alfredo Papa, Tim Raine, Fabio V. Teixeira, David T. Rubin, Silvio Danese, Laurent Peyrin-Biroulet

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based Guideline were to summarize available evidence and to provide practical recommendations regarding epidemiological aspects, prevention and drug-related risks of venous and arterial thrombotic events in patients with IBD. A virtual meeting took place in May 2020 involving 14 international IBD experts and 3 thrombosis experts from 12 countries. Proposed statements were voted upon in an anonymous manner. Agreement was defined as at least 75% of participants voting as ‘fully agree’ or ‘mostly agree’ with each statement. For each statement, the level of evidence was graded according to the Scottish Intercollegiate Guidelines Network (SIGN) grading system. Consensus was reached for 19 statements. Patients with IBD harbour an increased risk of venous and arterial thrombotic events. Thromboprophylaxis is indicated during hospitalization of any cause in patients with IBD. Disease activity is a modifiable risk factor in patients with IBD, and physicians should aim to achieve deep remission to reduce the risk. Exposure to steroids should be limited. Antitumour necrosis factor agents might be associated with a reduced risk of thrombotic events.
Lingua originaleEnglish
pagine (da-a)857-873
Numero di pagine17
RivistaNATURE REVIEWS. GASTROENTEROLOGY & HEPATOLOGY
Volume18
DOI
Stato di pubblicazionePubblicato - 2021

Keywords

  • Anti-Inflammatory Agents
  • Fibrinolytic Agents
  • Hospitalization
  • Humans
  • Inflammatory Bowel Diseases
  • International Cooperation
  • Patient Acuity
  • Risk Assessment
  • Risk Factors
  • Thrombosis

Fingerprint

Entra nei temi di ricerca di 'International consensus on the prevention of venous and arterial thrombotic events in patients with inflammatory bowel disease'. Insieme formano una fingerprint unica.

Cita questo